KR20220132042A - 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 - Google Patents

신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 Download PDF

Info

Publication number
KR20220132042A
KR20220132042A KR1020227032219A KR20227032219A KR20220132042A KR 20220132042 A KR20220132042 A KR 20220132042A KR 1020227032219 A KR1020227032219 A KR 1020227032219A KR 20227032219 A KR20227032219 A KR 20227032219A KR 20220132042 A KR20220132042 A KR 20220132042A
Authority
KR
South Korea
Prior art keywords
disease
compound
brain
agonist
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227032219A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 에스. 코리넥
제임스 디. 레흐라이터
시어도어 이. 리스톤
케네스 에이. 제이콥슨
Original Assignee
아스트로사이트 파마슈티컬스, 인코포레이티드
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트로사이트 파마슈티컬스, 인코포레이티드, 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템, 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 filed Critical 아스트로사이트 파마슈티컬스, 인코포레이티드
Publication of KR20220132042A publication Critical patent/KR20220132042A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227032219A 2016-04-21 2017-04-21 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 Ceased KR20220132042A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662325860P 2016-04-21 2016-04-21
US62/325,860 2016-04-21
KR1020187033797A KR102445887B1 (ko) 2016-04-21 2017-04-21 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
PCT/US2017/028996 WO2017185061A1 (en) 2016-04-21 2017-04-21 Compounds and methods for treating neurological and cardiovascular conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033797A Division KR102445887B1 (ko) 2016-04-21 2017-04-21 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법

Publications (1)

Publication Number Publication Date
KR20220132042A true KR20220132042A (ko) 2022-09-29

Family

ID=60022855

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227032219A Ceased KR20220132042A (ko) 2016-04-21 2017-04-21 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
KR1020187033797A Active KR102445887B1 (ko) 2016-04-21 2017-04-21 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187033797A Active KR102445887B1 (ko) 2016-04-21 2017-04-21 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법

Country Status (12)

Country Link
US (7) US12239654B2 (enExample)
EP (2) EP3445368B1 (enExample)
JP (3) JP7109005B2 (enExample)
KR (2) KR20220132042A (enExample)
CN (2) CN109310695B (enExample)
AU (2) AU2017254720B2 (enExample)
CA (1) CA3020490A1 (enExample)
EA (1) EA201892008A1 (enExample)
ES (1) ES2989621T3 (enExample)
IL (2) IL289423B2 (enExample)
MX (1) MX391725B (enExample)
WO (1) WO2017185061A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120628C2 (uk) 2014-11-07 2020-01-10 Басф Се Пестицидні суміші
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
CA3015456C (en) 2016-03-16 2024-09-17 Basf Se USE OF TETRAZOLINONES TO CONTROL RESISTANT PLANT PATHOGENIC FUNGI ON FRUIT
ES3056157T3 (en) 2016-03-16 2026-02-18 Basf Se Use of a specific tetrazolinone for combating resistant phytopathogenic fungi on cereals
EP3445368B1 (en) 2016-04-21 2024-07-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
CN112218638A (zh) * 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法
WO2019232554A2 (en) * 2018-05-26 2019-12-05 Primetime Life Sciences, Llc Compounds and methods for modulation of g-protein-coupled receptors
WO2020061211A1 (en) * 2018-09-18 2020-03-26 Saint Louis University Use of highly-selective adenosine 3a receptor subtype agonists
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
JP7282324B2 (ja) * 2018-12-11 2023-05-29 株式会社島津製作所 イオン化装置、質量分析装置および流体試料の分析方法
WO2020176544A1 (en) * 2019-02-25 2020-09-03 Saint Louis University Treatment of alzheimer's disease
JOP20210296A1 (ar) * 2019-05-06 2023-01-30 Ferrer Int صور جرعة صلبة صيدلية أو دوائية مغذية متعددة الطبقات ومشتملة على مشتقات بيريميدين و/أو بيورين وفيتامينات ب، وتحضيرها واستخداماتها
IL307967A (en) * 2021-04-28 2023-12-01 Astrocyte Pharmaceuticals Inc Purine nucleosides, their intermediates and methods for their preparation
KR20240122782A (ko) * 2021-11-22 2024-08-13 아스트로사이트 파마슈티컬스, 인코포레이티드 신경학적 및 심혈관 상태를 치료하는 방법
CA3250090A1 (en) * 2022-02-10 2023-08-17 Academia Sinica METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION
WO2024097387A1 (en) * 2022-11-03 2024-05-10 Astrocyte Pharmaceuticals, Inc. Compositions for intravenous administration
WO2024144874A2 (en) * 2022-11-03 2024-07-04 Astrocyte Pharmaceuticals, Inc. Fast-dissolving dosage forms and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002604A1 (en) 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7087589B2 (en) 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
US7589075B2 (en) 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
WO2003051881A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
GB0209539D0 (en) 2002-04-26 2002-06-05 Avecia Ltd Monomer Polymer and process
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
JP2007517019A (ja) * 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
JP2008512457A (ja) 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
EP2049127B1 (en) 2006-05-23 2014-11-26 University of Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2008021552A2 (en) 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20100047798A1 (en) 2006-11-08 2010-02-25 Thomas Jefferson University Adenosine a1 and a3 receptor gene sequence variations for predicting disease outcome and treatment outcome
US7867983B2 (en) 2007-03-29 2011-01-11 The University Of Connecticut Methods to protect skeletal muscle against injury
US20090088403A1 (en) 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
DE102007055529A1 (de) 2007-08-06 2009-02-12 Rhode & Schwarz Gmbh & Co. Kg Verfahren und Anordnung zum Erzeugen eines frequenzmodulierten Signals
JP5592262B2 (ja) 2007-10-15 2014-09-17 キャン−ファイト・バイオファーマ・リミテッド 肝細胞の増殖を誘導する方法及びその使用
BRPI0818578A2 (pt) 2007-10-17 2015-07-21 Novartis Ag Derivados de purina como ligantes receptores de adenosina a1
CN101925610A (zh) 2007-11-23 2010-12-22 巴尔-伊兰大学 不可水解的二磷酸核苷或三磷酸核苷衍生物及其用途
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
EP2331542B1 (en) 2008-08-01 2016-07-27 The United States of America, as Represented by The Secretary, Department of Health and Human Services A3 adenosine receptor antagonists and partial agonists
US8685372B2 (en) 2009-04-15 2014-04-01 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
US8518957B2 (en) 2009-12-02 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
US8822434B2 (en) 2010-02-22 2014-09-02 The University Of Connecticut Compositions and methods to treat cardiac diseases
US8691775B2 (en) 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
SI2968385T1 (sl) 2013-03-13 2018-10-30 Tufts University Uridin nukleozid derivati, sestavki in metode uporabe
US20150087613A1 (en) 2013-09-26 2015-03-26 Saint Louis University Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy
US9963450B2 (en) 2013-11-27 2018-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US20160024135A1 (en) 2014-07-27 2016-01-28 Zhejiang Subtropical Crops Research Institute Adenosine receptor activation reagent and the uses of thereof
HK1247119A1 (zh) 2015-02-04 2018-09-21 贝克心脏与糖尿病研究所 一种治疗方法和用於所述治疗方法中的化合物
RU2017129539A (ru) 2015-02-24 2019-03-25 Гальвани Байоэлектроникс Лимитед Устройство нейромодуляции
CN108685935B (zh) * 2015-05-06 2019-10-11 浙江省亚热带作物研究所 一种含有腺苷受体激动试剂的食品
EP3445368B1 (en) 2016-04-21 2024-07-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
US10683292B2 (en) 2016-07-25 2020-06-16 Nerviano Medical Sciences S.R.L. Purine and 3-deazapurine analogues as choline kinase inhibitors
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
CN112218638A (zh) 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法
KR102602990B1 (ko) 2018-06-27 2023-11-17 에스케이하이닉스 주식회사 전원 공급 장치 및 이를 포함하는 전자 장치
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
IL307967A (en) 2021-04-28 2023-12-01 Astrocyte Pharmaceuticals Inc Purine nucleosides, their intermediates and methods for their preparation
KR20240122782A (ko) 2021-11-22 2024-08-13 아스트로사이트 파마슈티컬스, 인코포레이티드 신경학적 및 심혈관 상태를 치료하는 방법

Also Published As

Publication number Publication date
JP7109005B2 (ja) 2022-07-29
KR20190006501A (ko) 2019-01-18
EP4414027A2 (en) 2024-08-14
US20220000899A1 (en) 2022-01-06
IL289423B1 (en) 2025-11-01
IL262487B (en) 2022-02-01
MX2018012655A (es) 2019-09-06
EP3445368A4 (en) 2019-12-18
IL289423B2 (en) 2026-03-01
ES2989621T3 (es) 2024-11-27
AU2017254720A1 (en) 2018-11-01
BR112018071560A2 (pt) 2019-02-12
WO2017185061A1 (en) 2017-10-26
MX391725B (es) 2025-03-21
IL289423A (en) 2022-02-01
US20180021363A1 (en) 2018-01-25
JP2022088642A (ja) 2022-06-14
US20250345353A1 (en) 2025-11-13
US10953031B2 (en) 2021-03-23
AU2023202694B2 (en) 2025-07-10
EP4414027A3 (en) 2024-11-13
US12239654B2 (en) 2025-03-04
EP3445368B1 (en) 2024-07-17
JP2025084908A (ja) 2025-06-03
EP3445368A1 (en) 2019-02-27
AU2017254720B2 (en) 2023-02-02
CN109310695B (zh) 2022-04-01
JP7709141B2 (ja) 2025-07-16
EP3445368C0 (en) 2024-07-17
US20200046751A1 (en) 2020-02-13
US11484545B2 (en) 2022-11-01
CN109310695A (zh) 2019-02-05
CA3020490A1 (en) 2017-10-26
CN114903903A (zh) 2022-08-16
US20230165887A1 (en) 2023-06-01
NZ747047A (en) 2025-02-28
US10265338B2 (en) 2019-04-23
IL262487A (en) 2018-12-31
KR102445887B1 (ko) 2022-09-21
JP2019515920A (ja) 2019-06-13
US20220305044A1 (en) 2022-09-29
US12390483B2 (en) 2025-08-19
EA201892008A1 (ru) 2019-06-28
US9789131B1 (en) 2017-10-17
AU2023202694A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
KR102445887B1 (ko) 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
Cui et al. Mdivi-1 protects against ischemic brain injury via elevating extracellular adenosine in a cAMP/CREB-CD39-dependent manner
JP7311855B2 (ja) 嗜癖および関連する障害を処置するための化合物および方法
KR20240122782A (ko) 신경학적 및 심혈관 상태를 치료하는 방법
HK40114882A (en) Compounds and methods for treating neurological and cardiovascular conditions
EA047947B1 (ru) Соединения и способы лечения неврологических и сердечно-сосудистых состояний
BR122024020857A2 (pt) Usos de um agonista para tratar condições neurológicas e cardiovasculares
BR112018071560B1 (pt) Usos de um agonista para tratar condições neurológicas e cardiovasculares
HK40004057A (en) Compounds and methods for treating neurological and cardiovascular conditions
HK40004057B (en) Compounds and methods for treating neurological and cardiovascular conditions
BR122024020857B1 (pt) Usos de um agonista para tratar condições neurológicas e cardiovasculares

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220916

Application number text: 1020187033797

Filing date: 20181121

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221017

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230103

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231027

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230103

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I